Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.
Authors
Singh, SCarnaghi, C
Buzzoni, R
Pommier, R
Raderer, M
Tomasek, J
Lahner, H
Valle, Juan W
Bubuteishvili-Pacaud, L
Lincy, J
Sachs, C
Okita, N
Libutti, S
Oh, D
Kulke, M
Strosberg, J
Yao, J
Pavel, M
Fazio, N
Affiliation
Sunnybrook Health Sciences Centre, Toronto, ONIssue Date
2016